Fresenius stock: JPMorgan keeps EUR 55.20 target, pre-market little changed
Published on 10/26/2026 at 08:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and trading setup
- David Adlington maintained JPMorgan’s Buy recommendation and EUR 55.20 target for Fresenius on October 26, 2026.
- Fresenius has scheduled its third-quarter results for November 4, 2026.
- Fresenius stock trades pre-market at EUR 46.04 at 8:23 a.m. CET at Lang & Schwarz on October 26, 2026, 0.13 percent below the Xetra close of October 23, 2026.
On October 26, 2026, JPMorgan analyst David Adlington maintained a Buy recommendation and a EUR 55.20 target for Fresenius, according to MarketScreener. Fresenius stock trades pre-market at EUR 46.04 at 8:23 a.m. CET at Lang & Schwarz on October 26, 2026, 0.13 percent below the Xetra close of October 23, 2026 (EUR 46.10).
JPMorgan maintains its target
The report identifies David Adlington as the JPMorgan analyst covering Fresenius and says the bank continues to view the shares positively. The EUR 55.20 target was maintained, while the recommendation remained Buy, according to the dated MarketScreener report.
Ahead of the Xetra open
The stock is EUR 0.06 below the Xetra close. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Fresenius stock.
The group and its next date
Fresenius develops, manufactures and sells medicines, equipment and medical devices used in hospital and home settings, earning revenue from healthcare products and services. The company’s investor-relations calendar lists the publication of third-quarter 2026 results for November 4, 2026, and its investor-relations page provides the schedule and company information. Market context: Market report DAX.
